JNJ-77242113-AAC Placebo tablet
Sponsors
Janssen Cilag International
Conditions
Active Psoriatic ArthritisModerately to Severely Active Crohn's DiseaseModerately to Severely Active Ulcerative Colitis
Phase 2
Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-naïve Participants with Active Psoriatic Arthritis
RecruitingCTIS2023-509239-19-00
Start: 2025-04-03Target: 337Updated: 2025-10-30
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the
Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-experienced Participants
with Active Psoriatic Arthritis
RecruitingCTIS2024-517284-23-00
Start: 2025-04-23Target: 401Updated: 2025-11-21
A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults with an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis
RecruitingCTIS2025-521381-10-00
Start: 2025-12-03Target: 391Updated: 2025-12-08